Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Stomach Neoplasms × Paclitaxel × Clear all

Status

Completed 50 Unknown 31 Recruiting 20 Active not recruiting 10 Terminated 7 Not yet recruiting 5 Withdrawn 3 Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1

Interventions

Ramucirumab 2 Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02307812 2025-01-09

Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France

Eli Lilly and Company

Approved for marketing

Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡